Bristol, Isis Team Up to Develop New Cardiovascular Drugs

Bristol-Myers Squibb and Isis Pharmaceuticals announced a collaboration to discover, develop and commercialize new drugs for the prevention and treatment of cardiovascular disease.

While Bristol-Myers Squibb will fund all activities under the collaboration, both companies will be responsible for preclinical development.

Bristol-Myers Squibb said it will pay Isis a $15 million upfront licensing fee, and will provide Isis with at least $9 million in research funding over a period of three years.

Isis will also receive up to $168 million for the achievement of pre-specified milestones for the first drug in the collaboration, as well as additional milestones associated with development of follow-on compounds.

Bristol-Myers Squibb said it will also pay Isis royalties on sales of products resulting from the collaboration.

Contact U.S. News


    Get the best of CNBC in your inbox

    To learn more about how we use your information,
    please read our Privacy Policy.
    › Learn More

Don't Miss

U.S. Video